
Andrew J Saxon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9038824/publications.pdf

Version: 2024-02-01



ΔΝΟΦΕΙΛΙ ΚΑΧΟΝ

#	Article	IF	CITATIONS
1	Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multiâ€site trial. Addiction, 2014, 109, 79-87.	1.7	345
2	Implications of Chronic Methamphetamine Use: A Literature Review. Harvard Review of Psychiatry, 2005, 13, 141-154.	0.9	332
3	Post-traumatic stress disorder and smoking: A systematic review. Nicotine and Tobacco Research, 2007, 9, 1071-1084.	1.4	225
4	Integrating Tobacco Cessation Into Mental Health Care for Posttraumatic Stress Disorder <subtitle>A Randomized Controlled Trial</subtitle> . JAMA - Journal of the American Medical Association, 2010, 304, 2485.	3.8	188
5	Longâ€ŧerm outcomes after randomization to buprenorphine/naloxone versus methadone in a multiâ€site trial. Addiction, 2016, 111, 695-705.	1.7	165
6	Factors affecting willingness to provide buprenorphine treatment. Journal of Substance Abuse Treatment, 2009, 36, 244-251.	1.5	150
7	A Pilot Trial of the Alphaâ€1 Adrenergic Antagonist, Prazosin, for Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2009, 33, 255-263.	1.4	147
8	Chronic pain among patients with opioid use disorder: Results from electronic health records data. Journal of Substance Abuse Treatment, 2017, 77, 26-30.	1.5	137
9	High Mortality Among Patients With Opioid Use Disorder in a Large Healthcare System. Journal of Addiction Medicine, 2017, 11, 315-319.	1.4	125
10	Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome. Addiction, 1996, 91, 1197-1210.	1.7	116
11	Trauma, Symptoms of Posttraumatic Stress Disorder, and Associated Problems Among Incarcerated Veterans. Psychiatric Services, 2001, 52, 959-964.	1.1	107
12	Divalproex Sodium in Alcohol Withdrawal: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Alcoholism: Clinical and Experimental Research, 2001, 25, 1324-1329.	1.4	105
13	Buprenorphine tapering schedule and illicit opioid use. Addiction, 2009, 104, 256-265.	1.7	103
14	Improving the Rates of Quitting Smoking for Veterans With Posttraumatic Stress Disorder. American Journal of Psychiatry, 2005, 162, 1311-1319.	4.0	102
15	The association of persistent pain with outâ€patient addiction treatment outcomes and service utilization. Addiction, 2008, 103, 1996-2005.	1.7	98
16	Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: A randomized trial. Drug and Alcohol Dependence, 2013, 128, 71-76.	1.6	94
17	HIV Risk Reduction With Buprenorphine–Naloxone or Methadone. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 288-293.	0.9	77
18	An Intronic Variant in OPRD1 Predicts Treatment Outcome for Opioid Dependence in African-Americans. Neuropsychopharmacology, 2013, 38, 2003-2010.	2.8	74

#	Article	IF	CITATIONS
19	A Pilot Trial of Prazosin, an Alphaâ€1 Adrenergic Antagonist, for Comorbid Alcohol Dependence and Posttraumatic Stress Disorder. Alcoholism: Clinical and Experimental Research, 2015, 39, 808-817.	1.4	73
20	High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. JAMA Network Open, 2021, 4, e2117128.	2.8	63
21	Brief motivational feedback improves post-incarceration treatment contact among veterans with substance use disorders. Drug and Alcohol Dependence, 2003, 69, 197-203.	1.6	60
22	The Addiction Severity Index medical and psychiatric composite scores measure similar domains as the SF-36 in substance-dependent veterans: concurrent and discriminant validity. Drug and Alcohol Dependence, 2004, 76, 165-171.	1.6	60
23	The Physician Clinical Support System-Buprenorphine (PCSS-B): a Novel Project to Expand/Improve Buprenorphine Treatment. Journal of General Internal Medicine, 2010, 25, 936-941.	1.3	59
24	Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder. American Journal of Psychiatry, 2018, 175, 1216-1224.	4.0	59
25	Analysis of Urinary Benzodiazepines Using Solid-Phase Extraction and Gas Chromatography-Mass Spectrometry. Journal of Analytical Toxicology, 1994, 18, 185-188.	1.7	56
26	A Comparison of Methamphetamine-Dependent Inpatients With and Without Childhood Attention Deficit Hyperactivity Disorder Symptomatology. Journal of Addictive Diseases, 2005, 24, 133-152.	0.8	56
27	Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Drug and Alcohol Dependence, 2020, 207, 107732.	1.6	55
28	Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine + Naloxone and Methadone. Journal of Addiction Medicine, 2017, 11, 63-69.	1.4	54
29	BuprenorphineÂ+Ânaloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction, 2016, 111, 1416-1427.	1.7	53
30	A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. Drug and Alcohol Dependence, 2017, 176, 79-88.	1.6	52
31	Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. Journal of NeuroImmune Pharmacology, 2018, 13, 488-497.	2.1	50
32	Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. , 2005, 108, 119-128.		49
33	Buprenorphine therapy for opioid addiction in rural Washington: The experience of the early adopters. Journal of Opioid Management, 2012, 8, 29-38.	0.2	49
34	An open trial of transdermal nicotine replacement therapy for smoking cessation among alcohol- and drug-dependent inpatients. Journal of Substance Abuse Treatment, 1997, 14, 333-337.	1.5	48
35	A double-blind, double-dummy, randomized, prospective pilot study of the partial Mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug and Alcohol Dependence, 2005, 77, 71-79.	1.6	48
36	From research to the real world: Buprenorphine in the decade of the Clinical Trials Network. Journal of Substance Abuse Treatment, 2010, 38, S53-S60.	1.5	45

#	Article	IF	CITATIONS
37	Retention in Methadone Maintenance Is Associated with Reductions in Different HIV Risk Behaviors for Women and Men. American Journal of Drug and Alcohol Abuse, 1996, 22, 509-521.	1.1	44
38	Genetic Determinants of Addiction to Opioids and Cocaine. Harvard Review of Psychiatry, 2005, 13, 218-232.	0.9	44
39	Slow tapering from methadone maintenance in a program encouraging indefinite maintenance. Journal of Substance Abuse Treatment, 2006, 30, 159-163.	1.5	44
40	Prevalence and trends of benzodiazepine use among Veterans Affairs patients with posttraumatic stress disorder, 2003–2010. Drug and Alcohol Dependence, 2012, 124, 154-161.	1.6	41
41	Implementation of buprenorphine in the Veterans Health Administration: Results of the first 3 years. Drug and Alcohol Dependence, 2007, 90, 292-296.	1.6	40
42	A narrative review: The effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients. American Journal on Addictions, 2016, 25, 452-465.	1.3	40
43	Integrating Tobacco Cessation Treatment into Mental Health Care for Patients with Posttraumatic Stress Disorder. American Journal on Addictions, 2006, 15, 336-344.	1.3	39
44	Prevalence and Trends of Concurrent Opioid Analgesic and Benzodiazepine Use Among Veterans Affairs Patients with Post-traumatic Stress Disorder, 2003–2011. Pain Medicine, 2015, 16, 1943-1954.	0.9	38
45	Methadone medical maintenance in primary care. Journal of General Internal Medicine, 2005, 20, 344-349.	1.3	37
46	Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. Addiction Science & Clinical Practice, 2019, 14, 11.	1.2	37
47	Medication-assisted treatment for opioid addiction: Methadone and buprenorphine. Journal of Food and Drug Analysis, 2013, 21, S69-S72.	0.9	36
48	Contingency Management of Urinalysis Results and Intensity of Counseling Services Have an Interactive Impact on Methadone Maintenance Treatment Outcome. Journal of Addictive Diseases, 1995, 13, 47-63.	0.8	35
49	Prevalence of Alcohol Misuse and Follow-Up Care in a National Sample of OEF/OIF VA Patients With and Without TBI. Psychiatric Services, 2017, 68, 48-55.	1.1	35
50	Longitudinal changes in injection behaviors in a cohort of injection drug users. Addiction, 1994, 89, 191-202.	1.7	34
51	Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems. Journal of Substance Abuse Treatment, 2020, 112, 41-48.	1.5	34
52	Associations of Housing Status With Substance Abuse Treatment and Service Use Outcomes Among Veterans. Psychiatric Services, 2010, 61, 698-706.	1.1	33
53	Alcohol-Related Nurse Care Management in Primary Care. JAMA Internal Medicine, 2018, 178, 613.	2.6	33
54	Personality Disorder Subtypes Among Cocaine and Opioid Addicts Using the Millon Clinical Multiaxial Inventory. Substance Use and Misuse, 1990, 25, 1037-1049.	0.6	31

#	Article	IF	CITATIONS
55	An Open-Label Pilot Study of Risperidone in the Treatment of Methamphetamine Dependence. Journal of Psychoactive Drugs, 2007, 39, 167-172.	1.0	30
56	Electronic Medical Record Alert Associated With Reduced Opioid and Benzodiazepine Coprescribing in High-risk Veteran Patients. Medical Care, 2018, 56, 171-178.	1.1	30
57	Acupuncture as an Adjunct to Methadone Treatment Services. American Journal on Addictions, 1995, 4, 198-214.	1.3	29
58	Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial. Lancet Psychiatry,the, 2021, 8, 287-300.	3.7	29
59	Integrating smoking cessation into mental health care for post-traumatic stress disorder. Clinical Trials, 2007, 4, 178-189.	0.7	28
60	Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial. Addiction Science & Clinical Practice, 2021, 16, 24.	1.2	28
61	Changes in Millon Clinical Multiaxial Inventory Scores Among Opiate Addicts as a Function of Retention in Methadone Maintenance Treatment and Recent Drug Use. American Journal of Drug and Alcohol Abuse, 2000, 26, 297-309.	1.1	27
62	Smoking intensity and severity of specific symptom clusters in posttraumatic stress disorder. Journal of Traumatic Stress, 2012, 25, 10-16.	1.0	27
63	PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment. Addiction Science & amp; Clinical Practice, 2021, 16, 9.	1.2	27
64	Outcome of contingency contracting for illicit drug use in a methadone maintenance program. Drug and Alcohol Dependence, 1993, 31, 205-214.	1.6	26
65	Effects of Psychiatric Care for Dual Diagnosis Patients Treated in a Drug Dependence Clinic. American Journal of Drug and Alcohol Abuse, 1995, 21, 303-313.	1.1	26
66	PTSD and depression as predictors of physical health-related quality of life in tobacco-dependent veterans. Journal of Psychosomatic Research, 2012, 73, 185-190.	1.2	26
67	Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories. American Journal on Addictions, 2015, 24, 667-675.	1.3	25
68	Extended-Release Naltrexone and Harm Reduction Counseling for Chronically Homeless People With Alcohol Dependence. Substance Abuse, 2015, 36, 21-33.	1.1	25
69	Disulfiram Use in Patients With Abnormal Liver Function Test Results. Journal of Clinical Psychiatry, 1998, 59, 313-316.	1.1	25
70	Smoking cessation treatment among dually diagnosed individuals: Preliminary evaluation of different pharmacotherapies. Nicotine and Tobacco Research, 2003, 5, 589-596.	1.4	24
71	The Influence of Posttraumatic Stress Disorder Numbing and Hyperarousal Symptom Clusters in the Prediction of Physical Health Status in Veterans With Chronic Tobacco Dependence and Posttraumatic Stress Disorder. Journal of Nervous and Mental Disease, 2011, 199, 940-945.	0.5	24
72	Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan. International Journal of Drug Policy, 2017, 43, 1-6.	1.6	24

#	Article	IF	CITATIONS
73	Quetiapine for the Treatment of Cocaine Dependence. Journal of Clinical Psychopharmacology, 2008, 28, 221-224.	0.7	23
74	Survey of Primary Care and Mental Health Prescribers' Perspectives on Reducing Opioid and Benzodiazepine Co-Prescribing Among Veterans. Pain Medicine, 2017, 18, pnw140.	0.9	23
75	Women in addictions treatment: comparing VA and community samples. Journal of Substance Abuse Treatment, 2002, 23, 41-48.	1.5	22
76	Smoking Outcome Expectancies in Military Veteran Smokers With Posttraumatic Stress Disorder. Nicotine and Tobacco Research, 2012, 14, 919-926.	1.4	22
77	Cocaine Use Reduction with Buprenorphine (CURB): Rationale, design, and methodology. Contemporary Clinical Trials, 2013, 34, 196-204.	0.8	22
78	Prevalence and Correlates of Cannabis Use and Cannabis Use Disorder Among U.S. Veterans: Results From the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC-III). American Journal of Psychiatry, 2022, 179, 26-35.	4.0	22
79	A system for uniform application of contingencies for illicit drug useâ~†. Journal of Substance Abuse Treatment, 1987, 4, 41-47.	1.5	21
80	Extendedâ€release naltrexone (XRâ€NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry. Addiction, 2018, 113, 1477-1487.	1.7	21
81	Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2†years: Results from a multisite randomized trial of adults with opioid use disorder. Journal of Substance Abuse Treatment, 2019, 106, 19-28.	1.5	21
82	Escalating Opioid Dose Is Associated With Mortality: A Comparison of Patients With and Without Opioid Use Disorder. Journal of Addiction Medicine, 2019, 13, 41-46.	1.4	21
83	Medications to treat cocaine use disorders. Current Opinion in Psychiatry, 2019, 32, 275-281.	3.1	19
84	Comparison of Medical Cannabis Use Reported on a Confidential Survey vs Documented in the Electronic Health Record Among Primary Care Patients. JAMA Network Open, 2022, 5, e2211677.	2.8	19
85	Prevalence of Medical Cannabis Use and Associated Health Conditions Documented in Electronic Health Records Among Primary Care Patients in Washington State. JAMA Network Open, 2021, 4, e219375.	2.8	18
86	Single Dose of 24 Milligrams of Buprenorphine for Heroin Detoxification: An Open-label Study of Five Inpatients. Journal of Psychoactive Drugs, 2006, 38, 505-512.	1.0	17
87	Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. Drug and Alcohol Dependence, 2021, 228, 108996.	1.6	17
88	Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System. JAMA Network Open, 2021, 4, e2137238.	2.8	17
89	Personality disorder subtypes among opiate addicts in methadone maintenance Psychology of Addictive Behaviors, 1996, 10, 3-8.	1.4	16
90	Comparative Safety of Benzodiazepines and Opioids Among Veterans Affairs Patients With Posttraumatic Stress Disorder. Journal of Addiction Medicine, 2013, 7, 354-362.	1.4	16

#	Article	IF	CITATIONS
91	Survey of providers' attitudes toward integrating smoking cessation treatment into posttraumatic stress disorder care Psychology of Addictive Behaviors, 2013, 27, 249-255.	1.4	16
92	The Role of Cannabis Legalization in the Opioid Crisis. JAMA Internal Medicine, 2018, 178, 679.	2.6	16
93	Acceptability and Feasibility of a Mobile Health Application for Video Directly Observed Therapy of Buprenorphine for Opioid Use Disorders in an Office-based Setting. Journal of Addiction Medicine, 2020, 14, 319-325.	1.4	16
94	The Alcohol Use Disorders Identification Test (AUDIT) Predicts Alcohol Withdrawal Symptoms During Inpatient Detoxification. Journal of Addictive Diseases, 2002, 21, 81-91.	0.8	15
95	Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems. Addiction Science & Clinical Practice, 2021, 16, 46.	1.2	14
96	Substance use disorders and COVID-19: An analysis of nation-wide Veterans Health Administration electronic health records. Drug and Alcohol Dependence, 2022, 234, 109383.	1.6	14
97	Validity of the MCMI drug abuse scale with drug abusing and psychiatric samples. Journal of Clinical Psychology, 1990, 46, 244-246.	1.0	13
98	Longitudinal analysis of the relationship between PTSD symptom clusters, cigarette use, and physical health-related quality of life. Quality of Life Research, 2013, 22, 1381-1389.	1.5	13
99	Quetiapine for the treatment of cocaine use disorder. Drug and Alcohol Dependence, 2015, 149, 18-24.	1.6	13
100	Further Validation of the Alcohol Dependence Scale as an Index of Severity*. Journal of Studies on Alcohol and Drugs, 2007, 68, 149-156.	0.6	12
101	Open Trial of Injectable Risperidone for Methamphetamine Dependence. Journal of Addiction Medicine, 2009, 3, 55-65.	1.4	12
102	Providing intensive addiction/housing case management to homeless veterans enrolled in addictions treatment: A randomized controlled trial Psychology of Addictive Behaviors, 2017, 31, 231-241.	1.4	12
103	Characteristics and service utilization of homeless veterans entering VA substance use treatment Psychological Services, 2017, 14, 208-213.	0.9	12
104	Trends in Prescriptions for Non-opioid Pain Medications Among U.S. Adults With Moderate or Severe Pain, 2014-2018. Journal of Pain, 2022, 23, 1187-1195.	0.7	12
105	Some Additional Considerations Regarding the American Society of Addiction Medicine National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Journal of Addiction Medicine, 2016, 10, 140-142.	1.4	11
106	Developing a clinical decision support for opioid use disorders: a NIDA center for the clinical trials network working group report. Addiction Science & Clinical Practice, 2020, 15, 4.	1.2	11
107	Pain, cannabis use, and physical and mental health indicators among veterans and nonveterans: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Pain, 2022, 163, 267-273.	2.0	11
108	Detecting Bipolar Disorder Among Treatment-Seeking Substance Abusers. American Journal of Drug and Alcohol Abuse, 2000, 26, 13-23.	1.1	10

#	Article	IF	CITATIONS
109	Relationship of Phosphatidylethanol Biomarker to Selfâ€Reported Alcohol Drinking Patterns in Older and Middleâ€Age Adults. Alcoholism: Clinical and Experimental Research, 2020, 44, 2449-2456.	1.4	10
110	Video directly observed therapy for patients receiving office-based buprenorphine $\hat{a} \in A$ pilot randomized controlled trial. Drug and Alcohol Dependence, 2021, 227, 108917.	1.6	10
111	Cost-Effectiveness of Integrating Tobacco Cessation Into Post-Traumatic Stress Disorder Treatment. Nicotine and Tobacco Research, 2016, 18, 267-274.	1.4	9
112	Harm Reduction Treatment for Smoking (HaRT-S): Findings from a Single-Arm Pilot Study with Smokers Experiencing Chronic Homelessness. Substance Abuse, 2019, 40, 229-239.	1.1	9
113	Primary Care and Mental Health Prescribers, Key Clinical Leaders, and Clinical Pharmacist Specialists' Perspectives on Opioids and Benzodiazepines. Pain Medicine, 2021, 22, 1559-1569.	0.9	9
114	Can an Immunoassay Become a Standard Technique in Detecting Oxycodone and Its Metabolites?. Journal of Analytical Toxicology, 2005, 29, 825-829.	1.7	8
115	Clinical monitoring and high-risk conditions among patients with SUD newly prescribed opioids and benzodiazepines. Drug and Alcohol Dependence, 2014, 142, 24-32.	1.6	8
116	Harm reduction with pharmacotherapy for homeless people with alcohol dependence: Protocol for a randomized controlled trial. Contemporary Clinical Trials, 2014, 38, 221-234.	0.8	8
117	Tobacco use trajectories among a large cohort of treated smokers with posttraumatic stress disorder. Addictive Behaviors, 2015, 41, 238-246.	1.7	8
118	Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use Disorder. Journal of Addiction Medicine, 2020, 14, e188-e194.	1.4	8
119	Longâ€ŧerm followâ€up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction, 2022, 117, 151-161.	1.7	8
120	Validity of the MCMI Drug Abuse Scale Varies as a Function of Drug Choice, Race, and Axis II Subtypes. American Journal of Drug and Alcohol Abuse, 1991, 17, 153-159.	1.1	7
121	Using the General Behavior Inventory to Screen for Mood Disorders Among Patients With Psychoactive Substance Dependence. American Journal on Addictions, 1994, 3, 296-305.	1.3	7
122	Clinical Issues Related to the Costs of Alcoholism. Pharmacoeconomics, 1996, 9, 134-145.	1.7	7
123	Medication-assisted therapy for opioid addiction. Journal of Food and Drug Analysis, 2013, 21, S13-S15.	0.9	7
124	Prevalence and Medication Treatment of Opioid Use Disorder Among Primary Care Patients with Hepatitis C and HIV. Journal of General Internal Medicine, 2021, 36, 930-937.	1.3	7
125	Commentary on Burns <i>et al</i> . (2015): Retention in buprenorphine treatment. Addiction, 2015, 110, 656-657.	1.7	6
126	A Guide for Applying to Addiction Psychiatry Fellowship. Academic Psychiatry, 2020, 44, 135-140.	0.4	6

#	Article	IF	CITATIONS
127	Non-pharmacological Treatment for Chronic Pain in US Veterans Treated Within the Veterans Health Administration: Implications for Expansion in US Healthcare Systems. Journal of General Internal Medicine, 2022, 37, 3937-3946.	1.3	6
128	Clinical Documentation of Patient-Reported Medical Cannabis use in Primary Care: Toward Scalable Extraction using Natural Language Processing Methods. Substance Abuse, 2022, 43, 917-924.	1.1	6
129	Marijuana not ready for prime time as an analgesic. General Hospital Psychiatry, 2014, 36, 4-6.	1.2	5
130	The Unmet Challenges of Coâ€Occurring Alcohol and Opioid Use. Alcoholism: Clinical and Experimental Research, 2018, 42, 1406-1407.	1.4	5
131	Using the General Behavior Inventory to Screen for Mood Disorders Among Patients with Psychoactive Substance Dependence. American Journal on Addictions, 1994, 3, 296-305.	1.3	5
132	Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials. International Journal of Environmental Research and Public Health, 2022, 19, 4106.	1.2	5
133	Integrating Routine Screening for Opioid Use Disorder into Primary Care Settings: Experiences from a National Cohort of Clinics. Journal of General Internal Medicine, 2023, 38, 332-340.	1.3	5
134	Comparison of HIVâ€Associated Risk Behaviors of Primary Intravenous Stimulant Users and Opioidâ€Addicted Subjects on Methadone Maintenance. American Journal on Addictions, 1992, 1, 304-314.	1.3	4
135	Transporting efficacious treatments from academia to community: barriers and opportunities. Drug and Alcohol Dependence, 2003, 70, 127-129.	1.6	4
136	Use of Prolonged Exposure and Sertraline in the Treatment of Posttraumatic Stress Disorder for Veterans. JAMA Psychiatry, 2019, 76, 109.	6.0	4
137	Use of Veterans Affairs Health Care Services by Veterans Receiving Addiction Treatment in Washington State Psychological Services, 2004, 1, 120-125.	0.9	3
138	Comparative safety of methadone and buprenorphine. Lancet Psychiatry, the, 2015, 2, 855-856.	3.7	3
139	Potential for Precision Medicine in Methadone Treatment of Opioid Use Disorder. Journal of Addiction Medicine, 2020, 14, 362-363.	1.4	3
140	Outcome of a second episode of methadone maintenance. Drug and Alcohol Dependence, 1996, 43, 163-168.	1.6	2
141	The Use of Urine Toxicology to Enhance Patient Control of Take-Home Doses in Methadone Maintenance: Effects on Reducing Illicit Drug Use. Addiction Research, 1998, 6, 203-214.	0.6	2
142	Pharmacokinetic Profile of an Oral Loading Dose of Divalproex Sodium During Acute Alcohol Withdrawal. Journal of Clinical Psychopharmacology, 2006, 26, 105-107.	0.7	2
143	LONG-SUFFERING OR PROLONGED SUFFERING? TIME MATTERS. Addiction, 2009, 104, 1429-1430.	1.7	2
144	Long-term Buprenorphine Treatment for Loperamide Use Disorder: A Case Series. Journal of Addiction Medicine. 2020, 14, e378-e381.	1.4	2

#	Article	IF	CITATIONS
145	Elevated customary alcohol consumption attenuates opioid effects. Pharmacology Biochemistry and Behavior, 2021, 211, 173295.	1.3	2
146	A Pilot Study Comparing Severely and Persistently Mentally III Opiateâ€Addicted Patients in Dualâ€Diagnosis Treatment With Patients in Methadone Maintenance. American Journal on Addictions, 1998, 7, 288-298.	1.3	1
147	Methadone "callbacks―within a veterans affairs opioid treatment program: Detecting methadone misuse. American Journal on Addictions, 2017, 26, 50-52.	1.3	1
148	Prazosin for Alcohol Use Disorder: Response to Kleinman and Ostacher. American Journal of Psychiatry, 2019, 176, 165-166.	4.0	1
149	Imperative for Attention to Opioid Use Disorder and Other Substance Use Disorders in Older Adults. American Journal of Geriatric Psychiatry, 2021, 29, 429-431.	0.6	1
150	Urine Screening for Marijuana Among Methadone-Maintained Patients. American Journal on Addictions, 1993, 2, 207-211.	1.3	1
151	Buprenorphine in safety-sensitive positions. American Journal of Drug and Alcohol Abuse, 2022, , 1-5.	1.1	1
152	Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene. European Journal of Clinical Pharmacology, 2022, 78, 965-973.	0.8	1
153	The Addiction Solution: Treating Our Dependence on Opioids and Other Drugsby Lloyd I. Sederer, M.D. New York, Simon & Schuster, 2018, 224 pp., \$26.00 (hardcover) American Journal of Psychiatry, 2018, 175, 688-689.	4.0	0
154	Comparison of HIV-Associated Risk Behaviors of Primary Intravenous Stimulant Users and Opioid-Addicted Subjects on Methadone Maintenance. American Journal on Addictions, 1992, 1, 304-314.	1.3	0
155	Introduction to the Special Series: National Drug Abuse Treatment Clinical Trials Network and the Opioid Use Disorder Care Continuum—20 years of research informing practice. Addiction Science & Clinical Practice, 2022, 17, 7.	1.2	0